Skip to main content
main-content

Type 2 diabetes medications

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Support for metformin cardioprotective effect

Heartbeat

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

medwireNews top story

Real-world data reassure on severe UTI risk with SGLT2 inhibition

Urine test strip

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.

medwireNews feature

Fournier gangrene: A challenge for risk–benefit communication

Doctor patient consultation

The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

The REWIND trial

Cardiovascular disease (illustration)
ADA 2019

The DUAL VIII trial

Insulin pens
ADA 2019

The PIONEER trials

diabetes_pills_syringe
Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Sulfonylurea pill

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

medwireNews top story

Postmarketing data support Fournier gangrene link with SGLT2 inhibitors

Critical care

Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.

medwireNews

08-09-2019 | Insulin | News

Weight loss differences seen with fixed vs flexible insulin, GLP-1RA regimens

Patients initiating a flexible combination of basal insulin plus a glucagon-like peptide-1 receptor agonist have similar improvements in glycemic control to those initiating a fixed combination, but with greater weight loss, real-world study data show.

08-06-2019 | Metformin | Highlight | News

Support for metformin cardioprotective effect

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

07-29-2019 | SGLT2 inhibitors | Highlight | News

Real-world data reassure on severe UTI risk with SGLT2 inhibition

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-27-2018 | Insulin | Article

Insulin injection technique questionnaire: Results of an international study comparing Brazil, Latin America and World data

Calliari LE et al. Diabetol Metab Syndr 2018; 10: 85. doi: 10.1186/s13098-018-0389-3

11-15-2018 | Pregnancy | Article

Successful outcomes with insulin degludec in pregnancy: A case series

Hiranput S et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0532-z

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits